nicotinamide-beta-riboside and Cardiomyopathies

nicotinamide-beta-riboside has been researched along with Cardiomyopathies* in 3 studies

Reviews

1 review(s) available for nicotinamide-beta-riboside and Cardiomyopathies

ArticleYear
Nicotinamide Riboside for the Prevention and Treatment of Doxorubicin Cardiomyopathy. Opportunities and Prospects.
    Nutrients, 2021, Sep-28, Volume: 13, Issue:10

    Despite the progress in the development of new anticancer strategies, cancer is rapidly spreading around the world and remains one of the most common diseases. For more than 40 years, doxorubicin has been widely used in the treatment of solid and hematological tumors. At the same time, the problem of its cardiotoxicity remains unresolved, despite the high efficiency of this drug. Symptomatic therapy is used as a treatment for side-effects of doxorubicin or pathological conditions that have already appeared in their background. To date, there are no treatment methods for doxorubicin cardiomyopathy as such. A drug such as nicotinamide riboside can play an important role in solving this problem. Nicotinamide riboside is a pyridine nucleoside similar to vitamin B3 that acts as a precursor to NAD

    Topics: Animals; Antibiotics, Antineoplastic; Biomarkers; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Disease Management; Disease Models, Animal; Disease Susceptibility; Doxorubicin; Humans; Metabolic Networks and Pathways; NAD; Niacinamide; Oxidative Stress; Pyridinium Compounds; Signal Transduction; Sirtuins

2021

Other Studies

2 other study(ies) available for nicotinamide-beta-riboside and Cardiomyopathies

ArticleYear
Intravenous Nicotinamide Riboside Administration Has a Cardioprotective Effect in Chronic Doxorubicin-Induced Cardiomyopathy.
    International journal of molecular sciences, 2022, Oct-28, Volume: 23, Issue:21

    Doxorubicin, which is widely used to treat a broad spectrum of malignancies, has pronounced dose-dependent side effects leading to chronic heart failure development. Nicotinamide riboside (NR) is one of the promising candidates for leveling the cardiotoxic effect. In the present work, we performed a comparative study of the cardioprotective and therapeutic actions of various intravenous NR administration modes in chronic doxorubicin-induced cardiomyopathy in Wistar rats. The study used 60 mature male SPF Wistar rats. The animals were randomized into four groups (a control group and three experimental groups) which determined the doxorubicin (intraperitoneally) and NR (intravenous) doses as well as the specific modes of NR administration (combined, preventive). We demonstrated the protective effect of NR on the cardiovascular system both with combined and preventive intravenous drug administration, which was reflected in a fibrous tissue formation decrease, reduced fractional-shortening decrease, and better antioxidant system performance. At the same time, it is important to note that the preventive administration of NR had a more significant protective effect on the animal organism as a whole. This was confirmed by better physical activity parameters and vascular bed conditions. Thus, the data obtained during the study can be used for further investigation into chronic doxorubicin-induced cardiomyopathy prevention and treatment approaches.

    Topics: Animals; Cardiomyopathies; Doxorubicin; Male; NAD; Niacinamide; Pyridinium Compounds; Rats; Rats, Wistar

2022
Lethal Cardiomyopathy in Mice Lacking Transferrin Receptor in the Heart.
    Cell reports, 2015, Oct-20, Volume: 13, Issue:3

    Both iron overload and iron deficiency have been associated with cardiomyopathy and heart failure, but cardiac iron utilization is incompletely understood. We hypothesized that the transferrin receptor (Tfr1) might play a role in cardiac iron uptake and used gene targeting to examine the role of Tfr1 in vivo. Surprisingly, we found that decreased iron, due to inactivation of Tfr1, was associated with severe cardiac consequences. Mice lacking Tfr1 in the heart died in the second week of life and had cardiomegaly, poor cardiac function, failure of mitochondrial respiration, and ineffective mitophagy. The phenotype could only be rescued by aggressive iron therapy, but it was ameliorated by administration of nicotinamide riboside, an NAD precursor. Our findings underscore the importance of both Tfr1 and iron in the heart, and may inform therapy for patients with heart failure.

    Topics: Animals; Cardiomyopathies; Cell Respiration; Iron; Mice; Mitophagy; Myocardium; Niacinamide; Pyridinium Compounds; Receptors, Transferrin

2015